We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared With Chemotherapy as Postremission Treatment of Children With Intermediate-risk Acute Myeloid Leukemia in First Complete Remission.
- Authors
Xue, Yu-juan; Cheng, Yi-fei; Lu, Ai-dong; Wang, Yu; Zuo, Ying-xi; Yan, Chen-hua; Suo, Pan; Zhang, Le-ping; Huang, Xiao-jun
- Abstract
<bold>Background: </bold>The role of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for children with intermediate-risk acute myeloid leukemia (IR-AML) in first complete remission has been controversial. The present study compared the effect of chemotherapy with unmanipulated haplo-HSCT as treatment of patients with IR-AML in first complete remission (CR1).<bold>Patients and Methods: </bold>We retrospectively analyzed the outcomes of 80 children with IR-AML and compared the effects of chemotherapy (n = 47) with those of haplo-HSCT (n = 33) as treatment in CR1.<bold>Results: </bold>The 3-year overall survival, event-free survival (EFS), and cumulative incidence of relapse (CIR) was 85.4% ± 4.1%, 73.2% ± 5.0%, and 25.4% ± 4.5%, respectively. Compared with the chemotherapy group, the patients in the haplo-HSCT group had a lower CIR (P = .059) and better EFS (P = .108), but roughly equivalent overall survival (P = .841). Multivariate analysis revealed chemotherapy and minimal residual disease (MRD) of ≥ 10-3 after induction therapy as independent risk factors affecting CIR and EFS. EFS (P = .045) and CIR (P = .045) differed significantly between the 2 treatment groups in patients with MRD of ≥ 10-3 after induction therapy.<bold>Conclusion: </bold>Haplo-HSCT might be a feasible option for children with IR-AML in CR1, especially for patients with MRD of ≥ 10-3 after induction therapy.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2021, Vol 21, Issue 2, pe126
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2020.09.004